Bristol Myers Squibb Co. stock rises Friday, still underperforms market
The stock's fall snapped a two-day winning streak.
Pfizer has increased prices on over 60 drugs in the U.S. as of Jan. 1
The U.S. continues to charge significantly higher prices for prescription drugs compared to similarly wealthy countries.
Companies sold a record $8 trillion of bonds last year amid high demand and lower borrowing costs
Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session.
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
PRINCETON, N.J., January 03, 2025 -- ( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will present at J.P. Morgan’s 43 rd Annual Healthcare Conference on Monday, ...
nationthailand20h
Drugmakers raised prices on 250+ medicines in the US starting Jan. 1
Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol ...
MM&M4h
Big Pharma hikes prices of 250 drugs in January
Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this month.
Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025
Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...
healthday8h
FDA Approves Subcutaneous Opdivo Qvantig for Most Solid Tumor Indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subc ...
General Proximity De-Stealths With $16M To Pioneer Next-Gen Induced Proximity Medicines For 'Undruggable' Targets
The company will use the capital to accelerate the development of treatments targeting undruggable proteins associated with canc ...
BlackDoctor5h
The Lack of Diverse Clinical Trials Have Real-Life Consequences
Dr. Robert A. Winn discusses efforts to increase diversity in clinical trials on an episode of Radio Health Journal.